{"entity":{"id":"crisantaspase","kind":"drug","name":"Crisantaspase (recombinant Erwinia asparaginase)","aka":["crisantaspase","Enrylaze","recombinant Erwinia chrysanthemi asparaginase","JZP-458"],"tldr":"Enrylaze is a replacement asparaginase for children and adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma whose bodies have reacted against, or quietly neutralised, the usual E. coli asparaginase. It keeps the asparagine-starving part of their chemotherapy going.","summary":"Crisantaspase (Enrylaze) is authorised in the EU since 15 September 2023 (CHMP opinion 20 July 2023; marketing authorisation holder Jazz Pharmaceuticals Ireland Limited) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukaemia and lymphoblastic lymphoma in adults and children from one month of age who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. It is under additional monitoring in the EU. The class record `asparaginase` covers pegaspargase, calaspargase pegol and the native Erwinia enzyme; this record is the recombinant Erwinia product.","status":"approved","asOf":"2026-09-22","links":[{"label":"EMA: Enrylaze (EPAR)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze"}],"tags":["ema-register"],"related":["asparaginase","eryaspase"],"cancers":["all-leukemia","all-paediatric-standard-risk","all-paediatric-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["jazz"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (EMA medicines register and EPAR pages)","editedOn":"2026-09-22"},"brand":"Enrylaze","modality":"Enzyme therapy (recombinant asparaginase)","mechanism":"Asparaginase enzyme that depletes circulating asparagine, on which lymphoblasts depend; the recombinant Erwinia enzyme is given to patients who have reacted to or silently inactivated E. coli-derived asparaginase (indication wording, EMA).","approvals":[{"region":"EU","year":2023,"indication":"ALL and lymphoblastic lymphoma, in a multi-agent regimen, after hypersensitivity or silent inactivation to E. coli-derived asparaginase (adults and children from 1 month)","note":"Authorised 15 Sep 2023; Jazz Pharmaceuticals Ireland"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/crisantaspase/","neighbours":{"drug":[{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/"},{"id":"eryaspase","kind":"drug","name":"Eryaspase","route":"/drugs/eryaspase/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/"}],"company":[{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/"}]}}